Technique Eliminates Need for Prolonged Immunosuppression in Kidney Transplants Technique Eliminates Need for Prolonged Immunosuppression in Kidney Transplants
Doctors at Stanford University School of Medicine in California say they have developed a way to transplant kidneys without the need for long-term immunosuppression.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2022 Category: Consumer Health News Tags: Transplantation News Source Type: news
Doctors Transplant Kidneys to Children Without Need for Immune-Suppressing Drugs
Title: Doctors Transplant Kidneys to Children Without Need for Immune-Suppressing DrugsCategory: Health NewsCreated: 6/16/2022 12:00:00 AMLast Editorial Review: 6/16/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - June 16, 2022 Category: Nutrition Source Type: news
Transplant Success Without Immune Suppressive Drugs
(MedPage Today) -- For three children, their newly transplanted kidneys might never require them to take immunosuppressive drugs.
Along with the kidney they got from a parent due to the rare T-cell immunodeficiency and primary kidney failure syndrome... (Source: MedPage Today Surgery)
Source: MedPage Today Surgery - June 15, 2022 Category: Surgery Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
